Shastri A, Adrianzen-Herrera DA. Ruxolitinib in CMML: A Case Study of Innovative Trial Design in a Rare Cancer.
Clin Cancer Res 2021;
27:6069-6071. [PMID:
34531297 DOI:
10.1158/1078-0432.ccr-21-2578]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2021] [Revised: 08/29/2021] [Accepted: 08/31/2021] [Indexed: 11/16/2022]
Abstract
Alternative statistical designs cannot fully mitigate the limitations of traditional clinical trials in rare cancers. Creative study designs that integrate early clinical data and correlative outcomes from concomitant translational and laboratory models to evaluate the efficacy of druggable targets can potentially expedite access to novel therapies for these patients.See related article by Hunter et al., p. 6095.
Collapse